Department of Chemistry, Hunter College, City University of New York, New York, New York.
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
J Nucl Med. 2024 Jul 1;65(7):998-1003. doi: 10.2967/jnumed.124.267546.
Gynecological pathologies account for approximately 4.5% of the overall global disease burden. Although cancers of the female reproductive system have understandably been the focus of a great deal of research, benign gynecological conditions-such as endometriosis, polycystic ovary syndrome, and uterine fibroids-have remained stubbornly understudied despite their astonishing ubiquity and grave morbidity. This historical inattention has frequently become manifested in flawed diagnostic and treatment paradigms. Molecular imaging could be instrumental in improving patient care on both fronts. In this Focus on Molecular Imaging review, we will examine recent advances in the use of PET, SPECT, MRI, and fluorescence imaging for the diagnosis and management of benign gynecological conditions, with particular emphasis on recent clinical reports, areas of need, and opportunities for growth.
妇科疾病约占全球疾病总负担的 4.5%。尽管女性生殖系统的癌症理所当然地成为了大量研究的焦点,但良性妇科疾病,如子宫内膜异位症、多囊卵巢综合征和子宫肌瘤,尽管其普遍性和严重的发病率令人惊讶,但仍未得到充分研究。这种历史上的忽视经常表现在有缺陷的诊断和治疗模式上。分子成像在这两个方面都有助于改善患者的护理。在这篇关于分子成像的综述中,我们将检查 PET、SPECT、MRI 和荧光成像在诊断和管理良性妇科疾病中的最新应用进展,特别强调最近的临床报告、需求领域和增长机会。